> BioMS Medical is raising $38.5 million through a private placement of 14 million shares. The company will use much of the money to advance clinical trials in MS. Release [1]
> Sepracor has promoted Adrian Adams to CEO. Report [2]
> FDA staffers say that Acambis' experimental smallpox vaccine is no worse than an older, discontinued drug and that it met two of four main goals. Acambis is seeking approval for a weakened version of the vaccine to treat the elderly and other vulnerable populations. Report [3]
> The FDA has approved Omrix's Evicel for use in vascular surgery. Researchers for the company say that Evicel creates a stable clot that anchors firmly to a bleeding site. Report [4]
And Finally...Dr. Mark Thornton, the former medical officer in the FDA's Office of Oncology Products, says that expert panel rejections of Provenge and Junovan mark a black day for cancer patients when it should have been heralding the dawn of a new era for immunotherapeutics. Report [5]
Links:
[1] http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=651907
[2] http://boston.bizjournals.com/boston/stories/2007/05/14/daily11.html?jst=b_ln_hl
[3] http://www.reuters.com/article/hotStocksNews/idUSN1539139920070515
[4] http://www.forbes.com/feeds/ap/2007/05/15/ap3721665.html
[5] http://online.wsj.com/article/SB117911315709601659.html?mod=googlenews_wsj